Kiniksa Pharmaceuticals Quarterly Income Statements Chart
Quarterly
|
Annual
Kiniksa Pharmaceuticals Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue: | |||||||||||||||||||||||||||||
| product revenue | 156,797,000 | 137,785,000 | 122,536,000 | 112,214,000 | 103,394,000 | 78,885,000 | 71,220,000 | 64,802,000 | 54,495,000 | 42,659,000 | 39,939,000 | 33,424,000 | 26,972,000 | 22,189,000 | 18,745,000 | 12,095,000 | 7,704,000 | ||||||||||||
| license and collaboration revenue | 5,237,000 | 973,000 | 12,175,000 | 2,244,000 | 16,978,000 | 5,686,000 | 21,945,000 | 65,711,000 | |||||||||||||||||||||
| total revenue | 156,797,000 | 137,785,000 | 122,536,000 | 112,214,000 | 108,631,000 | 79,858,000 | 83,395,000 | 67,046,000 | 71,473,000 | 48,345,000 | 61,884,000 | 99,135,000 | 26,972,000 | 32,189,000 | |||||||||||||||
| yoy | 44.34% | 72.54% | 46.93% | 67.37% | 51.99% | 65.18% | 34.76% | -32.37% | 164.99% | 50.19% | |||||||||||||||||||
| qoq | 13.80% | 12.44% | 9.20% | 3.30% | 36.03% | -4.24% | 24.38% | -6.19% | 47.84% | -21.88% | -37.58% | 267.55% | -16.21% | ||||||||||||||||
| costs and operating expenses: | |||||||||||||||||||||||||||||
| cost of goods sold | 18,603,000 | 17,868,000 | 17,896,000 | 20,109,000 | 12,322,000 | 10,583,000 | 9,584,000 | 9,088,000 | 7,699,000 | 7,036,000 | 6,710,000 | 6,937,000 | 5,029,000 | 4,219,000 | 3,867,000 | 2,767,000 | 2,466,000 | ||||||||||||
| collaboration expenses | 52,418,000 | 43,790,000 | 48,189,000 | 29,307,000 | 30,014,000 | 20,801,000 | 16,939,000 | 17,311,000 | 13,986,000 | 8,288,000 | 7,522,000 | 4,623,000 | 3,672,000 | 8,254,000 | |||||||||||||||
| research and development | 18,753,000 | 19,325,000 | 35,215,000 | 26,057,000 | 24,017,000 | 26,334,000 | 20,052,000 | 17,106,000 | 23,767,000 | 15,172,000 | 14,390,000 | 16,485,000 | 13,798,000 | 20,817,000 | 27,433,000 | 19,236,000 | 23,945,000 | 28,683,000 | 37,398,000 | 31,419,000 | 22,324,000 | 20,901,000 | 22,886,000 | 22,014,000 | 30,848,000 | 59,253,000 | 36,122,000 | 20,644,000 | 17,200,000 |
| selling, general and administrative | 46,863,000 | 43,530,000 | 40,535,000 | 46,399,000 | 42,395,000 | 38,682,000 | 36,739,000 | 34,468,000 | 29,175,000 | 29,045,000 | 27,215,000 | 24,677,000 | 23,841,000 | 22,218,000 | 22,741,000 | 20,759,000 | 21,848,000 | 20,600,000 | |||||||||||
| total operating expenses | 136,637,000 | 124,513,000 | 141,835,000 | 121,872,000 | 108,748,000 | 96,400,000 | 83,314,000 | 77,973,000 | 74,627,000 | 59,541,000 | 55,837,000 | 52,722,000 | 46,340,000 | 55,508,000 | 54,876,000 | 42,762,000 | 48,259,000 | 49,283,000 | 52,898,000 | 43,218,000 | 31,860,000 | 29,387,000 | 32,581,000 | 30,446,000 | 39,289,000 | 67,647,000 | 44,135,000 | 26,159,000 | 21,527,000 |
| income from operations | 20,160,000 | 13,272,000 | -19,299,000 | -9,658,000 | -117,000 | -16,542,000 | 81,000 | -10,927,000 | -3,154,000 | -11,196,000 | 6,047,000 | 46,413,000 | -19,368,000 | -23,319,000 | -36,131,000 | -30,667,000 | -40,555,000 | -49,283,000 | -52,898,000 | -43,218,000 | -31,860,000 | -29,387,000 | -32,581,000 | -30,446,000 | -39,289,000 | -67,647,000 | -44,135,000 | -26,159,000 | |
| yoy | -17330.77% | -180.23% | -23925.93% | -11.61% | -96.29% | 47.75% | -98.66% | -123.54% | -83.72% | -51.99% | -116.74% | -251.35% | -52.24% | -52.68% | -31.70% | -29.04% | 27.29% | 67.70% | 62.36% | 41.95% | -18.91% | -56.56% | -26.18% | 16.39% | |||||
| qoq | 51.90% | -168.77% | 99.82% | 8154.70% | -99.29% | -20522.22% | -100.74% | 246.45% | -71.83% | -285.15% | -86.97% | -339.64% | -16.94% | -35.46% | 17.82% | -24.38% | -17.71% | -6.83% | 22.40% | 35.65% | 8.42% | -9.80% | 7.01% | -22.51% | -41.92% | 53.27% | 68.72% | ||
| operating margin % | 12.86% | 9.63% | -15.75% | -8.61% | -0.11% | -20.71% | 0.10% | -16.30% | -4.41% | -23.16% | 9.77% | 46.82% | -71.81% | -72.44% | |||||||||||||||
| other income | 2,717,000 | 2,293,000 | 2,320,000 | 2,457,000 | 2,421,000 | 2,266,000 | 2,369,000 | 2,428,000 | 1,915,000 | 1,832,000 | |||||||||||||||||||
| income before income taxes | 22,877,000 | 15,565,000 | -16,979,000 | -7,201,000 | 2,304,000 | -14,276,000 | 2,450,000 | -8,499,000 | -1,239,000 | -9,364,000 | 6,841,000 | 46,735,000 | |||||||||||||||||
| benefit from income taxes | -5,045,000 | -7,026,000 | -3,428,000 | -2,906,000 | -716,000 | -1,925,000 | -1,014,000 | ||||||||||||||||||||||
| net income | 17,832,000 | 8,539,000 | -8,888,000 | -12,693,000 | -3,908,000 | -17,704,000 | 25,237,000 | -13,855,000 | 14,972,000 | -12,270,000 | 4,461,000 | 224,093,000 | -19,981,000 | -25,210,000 | -36,333,000 | -30,544,000 | -41,563,000 | -49,484,000 | -53,657,000 | -43,836,000 | -37,469,000 | -26,419,000 | -31,797,000 | -27,058,000 | -37,191,000 | -65,821,000 | |||
| yoy | -556.29% | -148.23% | -135.22% | -8.39% | -126.10% | 44.29% | 465.73% | -106.18% | -174.93% | -51.33% | -112.28% | -833.67% | -51.93% | -49.05% | -32.29% | -30.32% | 10.93% | 87.30% | 68.75% | 62.01% | 0.75% | -59.86% | |||||||
| qoq | 108.83% | -196.07% | -29.98% | 224.80% | -77.93% | -170.15% | -282.15% | -192.54% | -222.02% | -375.05% | -98.01% | -1221.53% | -20.74% | -30.61% | 18.95% | -26.51% | -16.01% | -7.78% | 22.40% | 16.99% | 41.83% | -16.91% | 17.51% | -27.25% | -43.50% | ||||
| net income margin % | 11.37% | 6.20% | -7.25% | -11.31% | -3.60% | -22.17% | 30.26% | -20.66% | 20.95% | -25.38% | 7.21% | 226.05% | -74.08% | -78.32% | |||||||||||||||
| net income per share | 0.24 | 0.12 | -0.12 | -0.18 | -0.06 | -0.25 | 0.36 | -0.2 | 0.21 | -0.18 | 0.06 | 3.23 | -0.29 | -0.36 | -0.52 | -0.44 | -0.61 | -0.72 | -0.81 | -0.66 | -0.65 | -0.48 | -0.57 | -0.49 | -0.68 | -1.27 | -0.87 | -0.51 | -0.97 |
| weighted-average ordinary shares outstanding—basic | 73,438,530 | 72,647,121 | 71,424,159 | 71,004,640 | |||||||||||||||||||||||||
| weighted-average ordinary shares outstanding—diluted | 77,942,082 | 76,145,617 | 71,424,159 | 71,004,640 | |||||||||||||||||||||||||
| comprehensive income | |||||||||||||||||||||||||||||
| other comprehensive income | |||||||||||||||||||||||||||||
| unrealized gain on short-term investments and currency translation adjustments, net of tax | 112 | -122 | 89 | -77 | -59 | 7 | -14 | -42 | 11 | 114 | 20 | 13 | -37 | 48 | 13 | -40 | -3 | -231 | 207 | -29 | -39 | ||||||||
| total other comprehensive income | 112 | -122 | 89 | -77 | -59 | 7 | -14 | -42 | 114 | 20 | 48 | 13 | -40 | -3 | -231 | 207 | -29 | -39 | 93 | 12 | |||||||||
| total comprehensive income | 17,944 | 8,537 | -3,985 | 25,244 | -13,869 | 14,930 | 4,575 | 224,113 | |||||||||||||||||||||
| other comprehensive loss | |||||||||||||||||||||||||||||
| unrealized loss on short-term investments and currency translation adjustments, net of tax | -2 | -2.75 | -72 | ||||||||||||||||||||||||||
| total other comprehensive loss | -2 | -2.75 | -72 | ||||||||||||||||||||||||||
| benefit for income taxes | 8,091,000 | -5,492,000 | -6,212,000 | 22,787,000 | -5,356,000 | 16,211,000 | -2,380,000 | 177,358,000 | -279,000 | 118,000 | -210,000 | -789,000 | -667,000 | -5,875,000 | 2,179,000 | -346,000 | 2,002,000 | 374,000 | 17,000 | -172,000 | 131,000 | 202,000 | |||||||
| weighted-average ordinary shares outstanding—basic and diluted | 71,726,685 | ||||||||||||||||||||||||||||
| comprehensive loss: | |||||||||||||||||||||||||||||
| other comprehensive income: | |||||||||||||||||||||||||||||
| total comprehensive loss | -8,588 | -12,604 | -17,763 | -12,259 | -19,968 | -25,247 | -36,354 | -30,616 | -41,515 | -49,471 | -53,697 | -43,839 | -37,700 | -26,212 | -31,826 | -27,097 | -37,098 | -65,809 | |||||||||||
| comprehensive income: | |||||||||||||||||||||||||||||
| weighted-average common shares outstanding—basic and diluted | 70,633,023 | 69,751,697 | 69,289,972 | 69,136,901 | 68,576,810 | 68,662,673 | 68,395,703 | 68,269,486 | 61,842,722 | 65,958,513 | 57,914,105 | 55,322,690 | 54,049,477 | 54,831,308 | 54,475,476 | 51,758,353 | 29,547,427 | 48,183,424 | 20,787,288 | ||||||||||
| weighted-average common shares outstanding—basic | 70,058,952 | 70,186,016 | 69,918,287 | 69,382,275 | 69,445,071 | ||||||||||||||||||||||||
| weighted-average common shares outstanding—diluted | 71,922,915 | 70,186,016 | 71,634,729 | 70,421,322 | 70,552,018 | ||||||||||||||||||||||||
| other comprehensive loss: | |||||||||||||||||||||||||||||
| total other comprehensive gain | 11 | 13 | -37 | ||||||||||||||||||||||||||
| interest income | 114,750 | 322,000 | 103,000 | 34,000 | 77,000 | 5,000 | 6,000 | 9,000 | 30,000 | 49,000 | 266,000 | 789,000 | 1,130,000 | 1,386,000 | 1,724,000 | 1,809,000 | 1,727,000 | 1,622,000 | 1,066,000 | ||||||||||
| collaboration revenue | 10,000,000 | ||||||||||||||||||||||||||||
| income before benefit from income taxes | -19,265,000 | -23,285,000 | -40,549,000 | -15,258,250 | -24,537,000 | ||||||||||||||||||||||||
| income before benefit for income taxes | -36,054,000 | -30,662,000 | -49,274,000 | -52,868,000 | -43,169,000 | -31,594,000 | -28,598,000 | -31,451,000 | -29,060,000 | -37,565,000 | -65,838,000 | ||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||
| general and administrative | 7,455,250 | 11,799,000 | 9,536,000 | 8,486,000 | 9,695,000 | 8,432,000 | 8,441,000 | 8,394,000 | 8,013,000 | 5,515,000 | 4,327,000 | ||||||||||||||||||
| unrealized gain on short-term investments | 93 | 12 | |||||||||||||||||||||||||||
| net income and comprehensive loss | -15,161,750 | -24,406,000 | -20,259,000 |
We provide you with 20 years income statements for Kiniksa Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Kiniksa Pharmaceuticals stock. Explore the full financial landscape of Kiniksa Pharmaceuticals stock with our expertly curated income statements.
The information provided in this report about Kiniksa Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.